Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, today announced that senior management will participate in the following investor conferences in October.
Nusano, Inc. has appointed pharmaceutical executive Alexandre Gibim as the company’s Chief Operations Officer (COO). Gibim will be responsible for enabling and scaling Nusano’s business functions to create a reliable domestic and global supply of medical radioisotopes, the active pharmaceutical ingredients (APIs) at the core of next-generation cancer therapeutics.
Video Replay: Unlocking the Next $20-30B Market Opportunity in Oncology: Radioisotope Production & Applications
With many now expecting radiopharamaceuticals to grow into a $20-30 billion market, investors are increasingly looking...
Nusano, Inc., a company working to stabilize and enable the production of cancer-fighting radioisotopes, is participating in two conferences in July 2023.
Nusano and PharmaLogic Announce Collaboration to Enable Next Generation Radiotherapeutics Development
Nusano and PharmaLogic will collaborate to advance the development of radiopharmaceuticals for diagnostic and therapeutic applications.
Nusano is creating an in-house stable isotope program to enhance the company’s medical radioisotope production capabilities and decrease dependence on foreign supply chains.
DISCOVER MORE ABOUT NUSANO
Sign up to receive company news and updates